Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice

Journal of Controlled Release

Volumn 172, Issue 3, 2013, Pages 1045-1064

  Stirland, Darren Lars ^a   Nichols, Joseph W ^a   Miura, Seiji ^b,c   Bae, You Han ^c  

^a Department of Electrical and Computer Engineering   (United States)

^b KOWA COMPANY LTD   (Japan)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Cancer therapy; Clinical translation; Drug carrier; Drug delivery; Nanomedicine

Indexed keywords

CANCER DRUG; CANCER THERAPY; CLINICAL SETTINGS; CLINICAL TRANSLATION; DRUG CARRIER; NANO-SIZED DRUG CARRIERS; OVER CURRENT; RESEARCH PAPERS;

CHEMOTHERAPY; MEDICAL NANOTECHNOLOGY;

DRUG DELIVERY;

AMINO ACID COPOLYMER; ANTINEOPLASTIC AGENT; CALAA 01; CALICHEAMICIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CISPLATIN DERIVATIVE; COPOLYMER; CREMOPHOR; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; FCE 28063; FLUOROURACIL; FREE DOXORUBICIN; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IODINE 131; LIPOSOME; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NAVELBINE; NC 6004; NK105; PACLITAXEL; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PK 1; PK 2; PK1; POLYASPARTIC ACID; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ASCITES TUMOR; BLADDER CANCER; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER RESEARCH; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; COLON ADENOCARCINOMA; COLON CARCINOMA; COLORECTAL CANCER; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG RETENTION; DRUG TISSUE LEVEL; DYSPNEA; FATIGUE; FIBROSARCOMA; GASTROINTESTINAL TOXICITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; HYPOTENSION; HYPOXIA; LEUKOPENIA; LEWIS CARCINOMA; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LIVER TOXICITY; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHATIC LEUKEMIA; LYMPHOMA; MALIGNANT MESOTHELIOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MICELLE; MICROTUBULE; MOUTH SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; MURINE LEUKEMIA; MYALGIA; MYELOID LEUKEMIA; NANOMEDICINE; NEOPLASM; NEPHROBLASTOMA; NEPHROTOXICITY; NEUROBLASTOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OTOTOXICITY; OVARY CANCER; OVARY CARCINOMA; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RECURRENT CANCER; RETICULOSARCOMA; REVIEW; SIDE EFFECT; SINUS BRADYCARDIA; SOFT TISSUE SARCOMA; STOMACH CANCER; STOMACH CARCINOMA; TESTIS CANCER; THROMBOCYTOPENIA; THYROID CANCER; TISSUE DISTRIBUTION; TRANSITIONAL CELL CARCINOMA; TUMOR LYSIS SYNDROME; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; WALKER CARCINOMA;

CANCER THERAPY; CLINICAL TRANSLATION; DRUG CARRIER; DRUG DELIVERY; NANOMEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, MOLECULAR; NANOSTRUCTURES; NEOPLASMS;

EID: 84887303593     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.09.026     Document Type: Review

References (187)

1. M.C. Roco Nanotechnology: convergence with modern biology and medicine Curr. Opin. Biotechnol. 14 2003 337 346 (Pubitemid 36782666)
2. V. Wagner, A. Dullaart, A.-K. Bock, and A. Zweck The emerging nanomedicine landscape Nat. Biotechnol. 24 2006 1211 1217 (Pubitemid 44564760)
3. N. Nasongkla, E. Bey, J. Ren, H. Ai, C. Khemtong, and J.S. Guthi Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems Nano Lett. 6 2006 2427 2430 (Pubitemid 46076928)
4. J.C. Pickup, Z. Zhi, F. Khan, T. Saxl, and D.J.S. Birch Nanomedicine and its potential in diabetes research and practice Diabetes Metab. Res. Rev. 24 2008 604 610
5. S. Gelperina, K. Kisich, M.D. Iseman, and L. Heifets The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis Am. J. Respir. Crit. Care Med. 172 2005 1487 1490 (Pubitemid 43076534)
6. U. Pison, T. Welte, M. Giersig, and D.A. Groneberg Nanomedicine for respiratory diseases Eur. J. Pharmacol. 533 2006 341 350 (Pubitemid 43340025)
7. A.V. Kabanov, and H.E. Gendelman Nanomedicine in the diagnosis and therapy of neurodegenerative disorders Prog. Polym. Sci. 32 2007 1054 1082 (Pubitemid 47198293)
8. R. Yatuv, M. Robinson, I. Dayan-Tarshish, and M. Baru The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia Int. J. Nanomedicine 5 2010 581 591
9. M. Vallet-Regí Nanostructured mesoporous silica matrices in nanomedicine J. Intern. Med. 267 2010 22 43
10. B.-B.S. Zhou, H. Zhang, M. Damelin, K.G. Geles, J.C. Grindley, and P.B. Dirks Tumour-initiating cells: challenges and opportunities for anticancer drug discovery Nat. Rev. Drug Discov. 8 2009 806 823
11. B.Y.S. Kim, J.T. Rutka, and W.C.W. Chan Nanomedicine N. Engl. J. Med. 363 2010 2434 2443
12. K. Riehemann, S.W. Schneider, T.A. Luger, B. Godin, M. Ferrari, and H. Fuchs Nanomedicine - challenge and perspectives Angew. Chem. Int. Ed. 48 2009 872 897 (in English)
13. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
14. P.P. Adiseshaiah, J.B. Hall, and S.E. McNeil Nanomaterial standards for efficacy and toxicity assessment Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 2009 99 112
15. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
16. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
17. Y. Matsumura, and K. Kataoka Preclinical and clinical studies of anticancer agent-incorporating polymer micelles Cancer Sci. 100 2009 572 579
18. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, and A. Yang Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143 (Pubitemid 40791578)
19. R. Duncan, L.W. Seymour, K.B. O'Hare, P.A. Flanagan, S. Wedge, and I.C. Hume Preclinical evaluation of polymer-bound doxorubicin J. Control. Release 19 1992 331 346
20. Z. Xu, W. Gu, J. Huang, H. Sui, Z. Zhou, and Y. Yang In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery Int. J. Pharm. 288 2005 361 368 (Pubitemid 40038589)
21. L. Paz-Ares, H. Ross, M. O'Brien, A. Riviere, U. Gatzemeier, and J. Von Pawel Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer Br. J. Cancer 98 2008 1608 1613 (Pubitemid 351684693)
22. M.E.R. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, and A. Santoro Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449 (Pubitemid 38444547)
23. S.K. Carter, A. Di Marco, and I.H. Krakoff International Symposium on Adriamycin: Milan, 9th-10th September, 1971 2012 Softcover, Springer London (Limited)
24. A. Di Marco Adriamycin (NSC-123127): mode and mechanism of action Cancer Chemother. Rep. 3 6 1975 91 106
25. M. Potmesil, Y.H. Hsiang, L.F. Liu, B. Bank, H. Grossberg, and S. Kirschenbaum Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II Cancer Res. 48 1988 3537 3543
26. R.B. Weiss The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19 1992 670 686 (Pubitemid 23004844)
27. M.A. Jordan Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr. Med. Chem. Anticancer Agents 2 2002 1 17 (Pubitemid 34649866)
28. Cancer Drug Information - Doxorubicin Hydrochloride, National Cancer Institute [Online]. Available at: http://www.cancer.gov/cancertopics/druginfo/ doxorubicinhydrochloride (Accessed: 08-Aug-2013)
29. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis, A.L. Von Hoff, and M. Rozencweig Risk factors for doxorubicin-induced congestive heart failure Ann. Intern. Med. 91 1979 710 717 (Pubitemid 10218041)
30. P.M. Alderton, J. Gross, and M.D. Green Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model Cancer Res. 52 1992 194 201
31. F. Rossi, W. Filippelli, S. Russo, A. Filippelli, and L. Berrino Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances Pharmacol. Toxicol. 75 1994 99 107 (Pubitemid 24257451)
32. J. Vásquez-Vivar, P. Martasek, N. Hogg, B.S. Masters, K.A. Pritchard, and B. Kalyanaraman Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin Biochemistry 36 1997 11293 11297 (Pubitemid 27408610)
33. S. Rajagopalan, P.M. Politi, B.K. Sinha, and C.E. Myers Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity Cancer Res. 48 1988 4766 4769
34. J.H. Doroshow, G.Y. Locker, and C.E. Myers Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin J. Clin. Invest. 65 1980 128 135 (Pubitemid 10214339)
35. Y. Barenholz Doxil® - the first FDA-approved nano-drug: lessons learned J. Control Release 160 2012 117 134
36. K.J. Harrington, S. Mohammadtaghi, P.S. Uster, D. Glass, A.M. Peters, and R.G. Vile Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes Clin. Cancer Res. 7 2001 243 254 (Pubitemid 32183025)
37. P.K. Working, and A.D. Dayan Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl) Hum. Exp. Toxicol. 15 1996 751 785 (Pubitemid 26331691)
38. D.M. Vail, M.A. Amantea, G.T. Colbern, F.J. Martin, R.A. Hilger, and P.K. Working Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies Semin. Oncol. 31 2004 16 35 (Pubitemid 40023240)
39. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436 (Pubitemid 36649037)
40. T. Siegal, A. Horowitz, and A. Gabizon Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy J. Neurosurg. 83 1995 1029 1037 (Pubitemid 26048143)
41. A.A. Gabizon, Y. Barenholz, and M. Bialer Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs Pharm. Res. 10 1993 703 708 (Pubitemid 23152316)
42. M. Amantea, M.S. Newman, T.M. Sullivan, A. Forrest, and P.K. Working Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs Hum. Exp. Toxicol. 18 1999 17 26 (Pubitemid 29054468)
43. A.A. Gabizon, O. Pappo, D. Goren, M. Chemla, D. Tzemach, and A.T. Horowitz Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes 2008
44. A.A. Gabizon Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes Cancer Res. 52 1992 891 896
45. J. Vaage, E. Barberá-Guillem, R. Abra, A. Huang, and P. Working Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts Cancer 73 1994 1478 1484 (Pubitemid 24072557)
46. A. Gabizon, D. Goren, A.T. Horowitz, D. Tzemach, A. Lossos, and T. Siegal Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals Adv. Drug Deliv. Rev. 24 1997 337 344 (Pubitemid 27112652)
47. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, and S.K. Huang Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U. S. A. 88 1991 11460 11464 (Pubitemid 21916061)
48. P.K. Working, M.S. Newman, T. Sullivan, and J. Yarrington Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes J. Pharmacol. Exp. Ther. 289 1999 1128 1133 (Pubitemid 29191275)
49. S.K. Huang, E. Mayhew, S. Gilani, D.D. Lasic, F.J. Martin, and D. Papahadjopoulos Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma Cancer Res. 52 1992 6774 6781 (Pubitemid 23006277)
50. J. Vaage, D. Donovan, P. Uster, and P. Working Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma Br. J. Cancer 75 1997 482 486 (Pubitemid 27085286)
51. J. Vaage, D. Donovan, E. Mayhew, R. Abra, and A. Huang Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes Cancer 72 1993 3671 3675 (Pubitemid 24000603)
52. G.T. Colbern, A.J. Hiller, R.S. Musterer, E. Pegg, I.C. Henderson, and P.K. Working Significant increase in antitumor potency of Doxorubicin Hc1 by its encapsulation in pegylated liposomes J. Liposome Res. 9 1999 523 538
53. A. Gabizon, and F. Martin Polyethylene glycol-coated (pegylated) liposomal doxorubicin Drugs 54 1997 15 21
54. P.K. Working, M.S. Newman, S.K. Huang, E. Mayhew, J. Vaage, and D.D. Lasic Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth® Liposomes (Doxil®) J. Liposome Res. 4 1994 667 687 (Pubitemid 24130564)
55. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, and R. Cohen Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992 (Pubitemid 24085451)
56. D.W. Northfelt, F.J. Martin, P. Working, P.A. Volberding, J. Russell, and M. Newman Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J. Clin. Pharmacol. 36 1996 55 63 (Pubitemid 26058811)
57. D.W. Northfelt Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma Oncology 11 1997 21 32
58. Z. Symon, A. Peyser, D. Tzemach, O. Lyass, E. Sucher, and E. Shezen Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes Cancer 86 1999 72 78 (Pubitemid 29293379)
59. D.S. Alberts, F.M. Muggia, J. Carmichael, E.P. Winer, M. Jahanzeb, and A.P. Venook Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials Semin. Oncol. 31 2004 53 90 (Pubitemid 40023242)
60. R. Soloman, and A.A. Gabizon Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin Clin. Lymphoma Myeloma 8 2008 21 32 (Pubitemid 351449716)
61. T. Safra, F. Muggia, S. Jeffers, D.D. Tsao-Wei, S. Groshen, and O. Lyass Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 Ann. Oncol. 11 2000 1029 1033
62. M.S. Ewer, F.J. Martin, C. Henderson, C.L. Shapiro, R.S. Benjamin, and A.A. Gabizon Cardiac safety of liposomal anthracyclines Semin. Oncol. 31 2004 161 181 (Pubitemid 40023246)
63. A. Gabizon, H. Shmeeda, and T. Grenader Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy Eur. J. Pharm. Sci. 45 2012 388 398
64. A. Udhrain, K.M. Skubitz, and D.W. Northfelt Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma Int. J. Nanomedicine 2 2007 345 352 (Pubitemid 350047778)
65. D.W. Northfelt, B.J. Dezube, J.A. Thommes, B.J. Miller, M.A. Fischl, and A. Friedman-Kien Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J. Clin. Oncol. 16 1998 2445 2451 (Pubitemid 28309039)
66. S. Stewart, H. Jablonowski, F.D. Goebel, K. Arasteh, M. Spittle, and A. Rios Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group J. Clin. Oncol. 16 1998 683 691 (Pubitemid 28135616)
67. M. Cianfrocca, S. Lee, J. Von Roenn, A. Tulpule, B.J. Dezube, and D.M. Aboulafia Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy Cancer 116 2010 3969 3977
68. L. Martin-Carbonero, A. Barrios, P. Saballs, G. Sirera, J. Santos, and R. Palacios Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma AIDS 18 2004 1737 1740 (Pubitemid 39095795)
69. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322 (Pubitemid 32642183)
70. A.N. Gordon, M. Tonda, S. Sun, and W. Rackoff Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol. Oncol. 95 2004 1 8 (Pubitemid 39286270)
71. R.M. Rifkin, S.A. Gregory, A. Mohrbacher, and M.A. Hussein Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial Cancer 106 2006 848 858 (Pubitemid 43238452)
72. R. Duncan Drug-polymer conjugates: potential for improved chemotherapy Anti-cancer Drugs 3 1992 175 210
73. F.M. Muggia Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention Clin. Cancer Res. 5 1999 7 8 (Pubitemid 29045171)
74. R. Duncan Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt Adv. Drug Deliv. Rev. 61 2009 1131 1148
75. A. Paul, M.J. Vicent, and R. Duncan Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates Biomacromolecules 8 2007 1573 1579 (Pubitemid 46865130)
76. T. Minko, P. Kopecková, V. Pozharov, and J. Kopecek HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line J. Control Release 54 1998 223 233 (Pubitemid 28342701)
77. T. Minko, P. Kopecková, and J. Kopecek Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells Pharm. Res. 16 1999 986 996 (Pubitemid 29368143)
78. T. Minko, P. Kopečková, and J. Kopeček Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line J. Control. Release 59 1999 133 148 (Pubitemid 29199920)
79. L.W. Seymour, K. Ulbrich, J. Strohalm, J. Kopecek, and R. Duncan The pharmacokinetics of polymer-bound adriamycin Biochem. Pharmacol. 39 1990 1125 1131 (Pubitemid 20103687)
80. L.W. Seymour, K. Ulbrich, P.S. Steyger, M. Brereton, V. Subr, and J. Strohalm Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma Br. J. Cancer 70 1994 636 641 (Pubitemid 24305589)
81. T. Minko, P. Kopecková, and J. Kopecek Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma Int. J. Cancer 86 2000 108 117 (Pubitemid 30133995)
82. L.W. Seymour, Y. Miyamoto, H. Maeda, M. Brereton, J. Strohalm, and K. Ulbrich Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier Eur. J. Cancer 31A 1995 766 770
83. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, and T. Akaike Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues Cancer Sci. 89 1998 307 314 (Pubitemid 28197296)
84. T. Minko, P. Kopeckova, V. Pozharov, K.D. Jensen, and J. Kopecek The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors Pharm. Res. 17 2000 505 514 (Pubitemid 30416386)
85. T.K. Yeung, J.W. Hopewell, R.H. Simmonds, L.W. Seymour, R. Duncan, and O. Bellini Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat Cancer Chemother. Pharmacol. 29 1991 105 111
86. B. Rihova, M. Bilej, V. Vetvicka, K. Ulbrich, J. Strohalm, and J. Kopecek Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro Biomaterials 10 1989 335 342 (Pubitemid 19174801)
87. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, and R. Duncan Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates Clin. Cancer Res. 5 1999 83 94 (Pubitemid 29045181)
88. L.W. Seymour, D.R. Ferry, D.J. Kerr, D. Rea, M. Whitlock, and R. Poyner Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer Int. J. Oncol. 34 2009 1629 1636
89. D. Guenard, F. Gueritte-Voegelein, and P. Potier Taxol and taxotere: discovery, chemistry, and structure-activity relationships Acc. Chem. Res. 26 1993 160 167
90. A. Stierle, G. Strobel, D. Stierle, P. Grothaus, and G. Bignami The search for a taxol-producing microorganism among the endophytic fungi of the Pacific Yew, Taxus brevifolia J. Nat. Prod. 58 1995 1315 1324
91. B. Ganem, and R.R. Franke Paclitaxel from primary taxanes: a perspective on creative invention in organozirconium chemistry J. Org. Chem. 72 2007 3981 3987 (Pubitemid 46846939)
92. S.B. Horwitz Taxol (paclitaxel): mechanisms of action Ann. Oncol. 5 Suppl. 6 1994 S3 S6
93. F. Dosio, P. Brusa, P. Crosasso, S. Arpicco, and L. Cattel Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate J. Control. Release 47 1997 293 304 (Pubitemid 27220212)
94. J. Szebeni, F.M. Muggia, and C.R. Alving Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study J. Natl. Cancer Inst. 90 1998 300 306 (Pubitemid 28182386)
95. E.K. Rowinsky, E.A. Eisenhauer, V. Chaudhry, S.G. Arbuck, and R.C. Donehower Clinical toxicities encountered with paclitaxel (Taxol) Semin. Oncol. 20 1993 1 15 (Pubitemid 23239390)
96. E.K. Rowinsky, N. Onetto, R.M. Canetta, and S.G. Arbuck Taxol: the first of the taxanes, an important new class of antitumor agents Semin. Oncol. 19 1992 646 662 (Pubitemid 23004842)
97. S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, and E. Lower Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J. Clin. Oncol. 23 2005 5542 5551
98. A. Moreno-Aspitia, and E.A. Perez Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer Future Oncol. 1 2005 755 762
99. M.R. Green, G.M. Manikhas, S. Orlov, B. Afanasyev, A.M. Makhson, and P. Bhar Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann. Oncol. 17 2006 1263 1268 (Pubitemid 44288216)
100. D.D. Von Hoff, R.K. Ramanathan, M.J. Borad, D.A. Laheru, L.S. Smith, and T.E. Wood Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J. Clin. Oncol. 29 2011 4548 4554
101. M. Tirrell Celgene Rises as Abraxane Meets Pancreatic Cancer Goals, Bloomberg 2012
102. N. Desai, V. Trieu, B. Damascelli, and P. Soon-Shiong SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients Transl. Oncol. 2 2009 59 64
103. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, and A. Yang Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin. Cancer Res. 12 2006 1317 1324 (Pubitemid 43342524)
104. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, and A. Yang Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143 (Pubitemid 40791578)
105. T.E. Stinchcombe, M.A. Socinski, C.M. Walko, B.H. O'Neil, F.A. Collichio, and A. Ivanova Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors Cancer Chemother. Pharmacol. 60 2007 759 766 (Pubitemid 47247287)
106. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, and P. Bhar Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 2005 7794 7803 (Pubitemid 46657376)
107. E. Miele, G.P. Spinelli, E. Miele, F. Tomao, and S. Tomao Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer Int. J. Nanomedicine 4 2009 99 105
108. A. Sparreboom, L. van Zuylen, E. Brouwer, W.J. Loos, P. de Bruijn, and H. Gelderblom Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res. 59 1999 1454 1457 (Pubitemid 29160110)
109. A.J. ten Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles Clin. Pharmacokinet. 42 2003 665 685
110. T. Hamaguchi, Y. Matsumura, M. Suzuki, K. Shimizu, R. Goda, and I. Nakamura NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 92 2005 1240 1246 (Pubitemid 40604398)
111. K. Kato, K. Chin, T. Yoshikawa, K. Yamaguchi, Y. Tsuji, and T. Esaki Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer Invest. New Drugs 30 2012 1621 1627
112. S.S. Wöhrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Oncol. 15 2004 1585 1595 (Pubitemid 39567288)
113. M. Findlay, D. Cunningham, A. Norman, J. Mansi, M. Nicolson, and T. Hickish A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF) Ann. Oncol. 5 1994 609 616 (Pubitemid 24283097)
114. P. Ross Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J. Clin. Oncol. 20 2002 1996 2004 (Pubitemid 34413593)
115. A. Webb, D. Cunningham, J. Scarffe, P. Harper, A. Norman, and J. Joffe Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J. Clin. Oncol. 15 1997 261 267 (Pubitemid 27020582)
116. T. Eguchi, M. Fujii, K. Wakabayashi, K. Aisaki, Y. Tsuneda, and M. Kochi Docetaxel plus 5-fluorouracil for terminal gastric cancer patients with peritoneal dissemination Hepatogastroenterology 50 2003 1735 1738 (Pubitemid 37186576)
117. S.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, and S.W. Kim In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Control. Release 72 2001 191 202 (Pubitemid 32522357)
118. T.-Y. Kim, D.-W. Kim, J.-Y. Chung, S.G. Shin, S.-C. Kim, and D.S. Heo Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin. Cancer Res. 10 2004 3708 3716 (Pubitemid 38697604)
119. S.Y. Lee, H.S. Park, K.Y. Lee, H.J. Kim, Y.J. Jeon, and T.W. Jang Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial Clin. Lung Cancer 14 2013 275 282
120. C. Li, D.-F. Yu, R.A. Newman, F. Cabral, L.C. Stephens, and N. Hunter Complete regression of well-established tumors using a novel water-soluble Poly(l-glutamic acid)-paclitaxel conjugate Cancer Res. 58 1998 2404 2409 (Pubitemid 28252701)
121. C. Li, J.E. Price, L. Milas, N.R. Hunter, S. Ke, and D.-F. Yu Antitumor activity of Poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors Clin. Cancer Res. 5 1999 891 897 (Pubitemid 29180842)
122. M.E.R. O'Brien, M.A. Socinski, I.N. Popovich, Alexander Y. Bondarenko, A. Tomova, B.T. Bilynsky, and Y.S. Hotko Randomized Phase III trial comparing single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naIve advanced non-small cell lung cancer J. Thorac. Oncol. 3 2008 728 734
123. P. Sabbatini, M.W. Sill, D. O'Malley, L. Adler, and A.A. Secord A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study Gynecol. Oncol. 111 2008 455 460
124. C.J. Langer, K.J. O'Byrne, M.A. Socinski, S.M. Mikhailov, K. Leśniewski-Kmak, and M. Smakal Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer J. Thorac. Oncol. 3 2008 623 630 (Pubitemid 351787307)
125. D.A. Richards, P. Richards, D. Bodkin, M.A. Neubauer, and F. Oldham Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study Clin. Lung Cancer 7 2005 215 220 (Pubitemid 43279872)
126. B. Rosenberg, L. VanCamp, and T. Krigas Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode Nature 205 1965 698 699
127. B. Rosenberg, L. VanCamp, E.B. Grimley, and A.J. Thomson The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes J. Biol. Chem. 242 1967 1347 1352
128. B. Rosenberg, E. Renshaw, L. Vancamp, J. Hartwick, and J. Drobnik Platinum-induced filamentous growth in Escherichia coli J. Bacteriol. 93 1967 716 721
129. B. Rosenberg, L. VanCamp, J.E. Trosko, and V.H. Mansour Platinum compounds: a new class of potent antitumour agents Nature 222 1969 385 386
130. B. Rosenberg, and L. VanCamp The successful regression of large solid sarcoma 180 tumors by platinum compounds Cancer Res. 30 1970 1799 1802
131. V. Cepeda, M.A. Fuertes, J. Castilla, C. Alonso, C. Quevedo, and J.M. Pérez Biochemical mechanisms of cisplatin cytotoxicity Anticancer Agents Med. Chem. 7 2007 3 18 (Pubitemid 46062402)
132. Cancer Drug Information - Cisplatin, National Cancer Institute [Online]. Available at: http://www.cancer.gov/cancertopics/druginfo/cisplatin (Accessed: 08-Aug-2013)
133. R.J. Kociba, and S.D. Sleight Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat Cancer Chemother. Rep. 1 55 1971 1 8
134. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115 124 (Pubitemid 47262919)
135. V. Pinzani, F. Bressolle, I.J. Haug, M. Galtier, J.P. Blayac, and P. Balmès Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review Cancer Chemother. Pharmacol. 35 1994 1 9 (Pubitemid 24356740)
136. J.T. Hartmann, and H.-P. Lipp Toxicity of platinum compounds Expert Opin. Pharmacother. 4 2003 889 901 (Pubitemid 36722480)
137. L. Helson, E. Okonkwo, L. Anton, and E. Cvitkovic cis-Platinum ototoxicity Clin. Toxicol. 13 1978 469 478 (Pubitemid 9170320)
138. D. Ding, B.L. Allman, and R. Salvi Review: ototoxic characteristics of platinum antitumor drugs Anat. Rec. (Hoboken) 295 2012 1851 1867
139. L.R. Kelland, and S.Y. Sharp Platinum compounds in cancer therapy, Current Opinion in Oncologic Endocr. Metab. Investig. Drugs 1 1999 380 385
140. I. Judson, and L.R. Kelland New developments and approaches in the platinum arena Drugs 59 Suppl. 4 2000 29 36 (discussion 37-8) (Pubitemid 30344989)
141. S.Y. Sharp, C.F. O'Neill, P. Rogers, F.E. Boxall, and L.R. Kelland Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin Eur. J. Cancer 38 2002 2309 2315 (Pubitemid 35346473)
142. M. Kartalou, and J.M. Essigmann Mechanisms of resistance to cisplatin Mutat. Res. 478 2001 23 43 (Pubitemid 32530848)
143. M. Yokoyama, T. Okano, Y. Sakurai, S. Suwa, and K. Kataoka Introduction of cisplatin into polymeric micelle J. Control. Release 39 1996 351 356 (Pubitemid 26195838)
144. N. Nishiyama, M. Yokoyama, T. Aoyagi, T. Okano, Y. Sakurai, and K. Kataoka Preparation and characterization of self-assembled polymer - metal complex micelle from cis -Dichlorodiammineplatinum(II) and Poly(ethylene glycol) - Poly(α, β-aspartic acid) block copolymer in an aqueous medium Langmuir 15 1999 377 383
145. N. Nishiyama, and K. Kataoka Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core J. Control Release 74 2001 83 94 (Pubitemid 32727612)
146. N. Nishiyama, Y. Kato, Y. Sugiyama, and K. Kataoka Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system Pharm. Res. 18 2001 1035 1041 (Pubitemid 32799952)
147. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, and Y. Sugiyama Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 63 2003 8977 8983 (Pubitemid 38064079)
148. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, and T. Honda Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 93 2005 678 687 (Pubitemid 41486459)
149. Y. Matsumura Poly (amino acid) micelle nanocarriers in preclinical and clinical studies Adv. Drug Deliv. Rev. 60 2008 899 914
150. K. Endo, T. Ueno, S. Kondo, N. Wakisaka, S. Murono, and M. Ito Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma Cancer Sci. 104 2013 369 374
151. M. Baba, Y. Matsumoto, A. Kashio, H. Cabral, N. Nishiyama, and K. Kataoka Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs J. Control Release 157 2012 112 117
152. R. Plummer, R.H. Wilson, H. Calvert, A.V. Boddy, M. Griffin, and J. Sludden A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Br. J. Cancer 104 2011 593 598
153. K. Kitajima, M. Fukuoka, S. Kobayashi, Y. Kusunoki, M. Takada, and S. Negoro [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity]., Gan to Kagaku Ryoho Cancer Chemother. 14 1987 2517 2523 (Pubitemid 18051281)
154. P.F. Bross, J. Beitz, G. Chen, X.H. Chen, E. Duffy, and L. Kieffer Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. 7 2001 1490 1496 (Pubitemid 32708610)
155. R.A. Larson, M. Boogaerts, E. Estey, C. Karanes, E.A. Stadtmauer, and E.L. Sievers Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16 2002 1627 1636
156. R.H.C. van der Jagt, C.C. Badger, F.R. Appelbaum, O.W. Press, D.C. Matthews, and J.F. Eary Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model Cancer Res. 52 1992 89 94
157. J.D. Griffin, D. Linch, K. Sabbath, P. Larcom, and S.F. Schlossman A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leuk. Res. 8 1984 521 534 (Pubitemid 14051256)
158. P.R. Hamann, L.M. Hinman, C.F. Beyer, D. Lindh, J. Upeslacis, and D.A. Flowers An anti-CD33 antibody - Calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker Bioconjug. Chem. 13 2002 40 46 (Pubitemid 34119633)
159. P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, and R. Holcomb Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody - Calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjug. Chem. 13 2002 47 58 (Pubitemid 34119634)
160. S. Petersdorf, K. Kopecky, R.K. Stuart, R.A. Larson, T.J. Nevill, and L. Stenke Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomiz ASH Annu. Meet. Abstr. 114 2009 790
161. FDA-News-Release, 2010 - FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market [Online]. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2010/ucm216448.htm (Accessed: 09-May-2013)
162. U. Brunnberg, M. Mohr, R. Noppeney, H.A. Dürk, M.C. Sauerland, and C. Müller-Tidow Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients Ann. Oncol. 23 2012 990 996
163. A.K. Burnett, R.K. Hills, D. Milligan, L. Kjeldsen, J. Kell, and N.H. Russell Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J. Clin. Oncol. 29 2011 369 377
164. P. Rajvanshi Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy Blood 99 2002 2310 2314 (Pubitemid 34525414)
165. L.W. Seymour Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin J. Clin. Oncol. 20 2002 1668 1676 (Pubitemid 34260549)
166. R. Duncan, L.C.W. Seymour, L. Scarlett, J.B. Lloyd, P. Rejmanová, and J. Kopeček Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats Biochim. Biophys. Acta Gen. Subj. 880 1986 62 71 (Pubitemid 16208729)
167. M.V. Pimm, A.C. Perkins, J. Strohalm, K. Ulbrich, and R. Duncan Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma J. Drug Target. 3 1996 385 390
168. P. Julyan Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine J. Control. Release 57 1999 281 290 (Pubitemid 29073443)
169. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
170. ClinicalTrials.gov. [Online] Available at: http://www.clinicaltrials.gov/ (Accessed: 06-Aug-2013)
171. UK Clinical Trials Gateway [Online]. Available at: http://www.ukctg.nihr. ac.uk/ (Accessed: 06-Aug-2013)
172. J.D. Heidel, and T. Schluep Cyclodextrin-containing polymers: versatile platforms of drug delivery materials J. Drug Deliv. 2012 2012 262731
173. S. Mishra, J.D. Heidel, P. Webster, and M.E. Davis Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes J. Control Release 116 2006 179 191 (Pubitemid 44854276)
174. K.C. Gatter, G. Brown, I.S. Trowbridge, R.E. Woolston, and D.Y. Mason Transferrin receptors in human tissues: their distribution and possible clinical relevance J. Clin. Pathol. 36 1983 539 545 (Pubitemid 13089724)
175. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 2009 659 668
176. J.D. Heidel, J.Y.-C. Liu, Y. Yen, B. Zhou, B.S.E. Heale, and J.J. Rossi Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo Clin. Cancer Res. 13 2007 2207 2215 (Pubitemid 46649891)
177. J.D. Heidel, Z. Yu, J.Y.-C. Liu, S.M. Rele, Y. Liang, and R.K. Zeidan Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA Proc. Natl. Acad. Sci. U. S. A. 104 2007 5715 5721 (Pubitemid 47175600)
178. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 104 2007 15549 15554 (Pubitemid 47502954)
179. M.E. Davis, J.E. Zuckerman, C.H.J. Choi, D. Seligson, A. Tolcher, and C.A. Alabi Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
180. D.W. Bartlett, and M.E. Davis Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles Biotechnol. Bioeng. 99 2008 975 985 (Pubitemid 351316639)
181. A. Ribas, L. Kalinoski, J.D. Heidel, J. Peterkin, D.B. Seligson, and J.E. Zuckerman Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: results from a first-in-class phase I clinical trial J. Clin. Oncol. 28 2010 (abstract 3022)
182. W.M. Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects [Online]. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (Accessed: 01-Aug-2013)
183. M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, and M. Tubiana-Hulin Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J. Clin. Oncol. 23 2005 4265 4274 (Pubitemid 46207001)
184. S. Chan, N. Davidson, E. Juozaityte, F. Erdkamp, A. Pluzanska, and N. Azarnia Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Ann. Oncol. 15 2004 1527 1534 (Pubitemid 39409744)
185. P. Gill, J. Wernz, D. Scadden, P. Cohen, G. Mukwaya, and J. von Roenn Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J. Clin. Oncol. 14 1996 2353 2364 (Pubitemid 26264888)
186. Z.-M. Wang, J.X. Ho, J.R. Ruble, J. Rose, F. Rüker, and M. Ellenburg Structural studies of several clinically important oncology drugs in complex with human serum albumin Biochim. Biophys. Acta 1830 12 2013 5356 5374
187. Y. Matsumura Polymeric micellar delivery systems in oncology Jpn. J. Clin. Oncol. 38 2008 793 802